Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
116 Results for "
AIN
" in MedChemExpress (MCE) Product Catalog:
Products (116)
116 Results for "AIN" in MCE Product Catalog:
Cat. No.: HY-162107
Target:
Research Areas:
Dyrk1A-IN-6 (compound 7cc) is an EGCG-like non-competitive inhibitor of DYRK1A. Dyrk1A-IN-6 can be used to alleviate cognitive defects in Down syndrome models .
Cat. No.: HY-147760
CAS No.: 2459657-37-3
Target:
Research Areas:
Dyrk1A-IN-2 (Compound 63) is a DYRK1A inhibitor with an EC50 of 37 nM. Dyrk1A-IN-2 exhibits highly potent human β-cell replication-promoting activity and low cytotoxicity .
Cat. No.: HY-142928
CAS No.: 2667053-18-9
Target:
Research Areas:
MAT2A-IN-1 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-1 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-1 has the potential for the research of cancer diseases (extracted from patent WO2021139775A1, compound 64) .
Cat. No.: HY-142929
CAS No.: 2565671-21-6
Target:
Research Areas:
MAT2A-IN-2 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-2 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-2 has the potential for the research of cancer diseases (extracted from patent WO2020243376A1, compound 172) .
Cat. No.: HY-142930
CAS No.: 2377493-28-0
Target:
Research Areas:
MAT2A-IN-3 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally high in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-3 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-3 has the potential for the research of cancer diseases (extracted from patent WO2019191470A1, compound 265) .
Cat. No.: HY-144181
CAS No.: 2756458-55-4
Research Areas:
MAT2A-IN-5 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-5 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-5 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 1) .
Cat. No.: HY-144184
CAS No.: 2756458-72-5
Research Areas:
MAT2A-IN-6 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-6 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-6 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 18) .
Cat. No.: HY-144185
CAS No.: 2756458-77-0
Research Areas:
MAT2A-IN-7 is a potent inhibitor of MAT2A. The expression level of MAT2A is abnormally elevated in several types of tumors, including gastric, colon, liver and pancreatic cancers. MAT2A-IN-7 reduces the proliferative activity of MTAP-deficient cancer cells. MAT2A-IN-7 has the potential for the potential for the research of cancer diseases (extracted from patent WO2021254529A1, compound 24) .
Cat. No.: HY-159496
CAS No.: 2891824-14-7
Target:
Research Areas:
Dyrk1A-IN-10 (compound B4) is a DYRK1A inhibitor with antidiabetic activity. Dyrk1A-IN-10 can promote pancreatic β-cell proliferation, increase insulin secretion, and lower blood sugar .
Cat. No.: HY-158683
Target:
Research Areas:
KIF18A-IN-11 (Compound 13) is a potent KIF18A inhibitor, with IC50 values of less than 100 nM in OVCAR3 and MDA-MB-157 cells. KIF18A-IN-11 can be used for the research of cancer .
Cat. No.: HY-176465
CAS No.: 3037959-47-7
Target:
Research Areas:
CES2A-IN-3 (Compound 9d) is a potent serine-targeting covalent human carboxylesterase 2A (hCES2A) inhibitor with an IC50 value of 0.12 nM. CES2A-IN-3 is promising for research of diarrhea and ulcerative colitis .
Cat. No.: HY-115981
CAS No.: 2764786-74-3
Target:
Research Areas:
NS5A-IN-2 (Compound 33) is a potent inhibitor of NS5A. NS5A-IN-2 has extremely high potency against HCV genotype 1b, improved activity against genotype 3a (GT 3a) and good metabolic stability . NS5A-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Cat. No.: HY-155228
Target:
Research Areas:
hCES2A-IN-2 (Compound 44) is an orally active human carboxylesterase 2 (hCES2A) inhibitor (IC50: 5.02 μM). hCES2A-IN-2 improves Irinotecan (HY-16562)-induced delayed diarrhea .
Cat. No.: HY-162531
CAS No.: 3034541-82-4
Target:
Research Areas:
KIF18A-IN-9 (Compound 1) is a potent KIF18A inhibitor, with an IC50 value of 3.8 nM. KIF18A-IN-9 has anticancer activity, with IC50 values of less than 100 nM in OVCAR3 and MDA-MB-157 cells .
Cat. No.: HY-U00427
CAS No.: 1426833-08-0
Target:
Research Areas:
PDE2A-IN-3 (Example Ic1) is a selective phosphodiesterase 2A (PDE2A) inhibitor with IC50s of 69 nM and 1762 nM for PDE2A and PDE10, respectively. PDE2A-IN-3 can be used for the study of neurological and psychiatric disorders .
Cat. No.: HY-162532
CAS No.: 3034542-28-1
Target:
Research Areas:
KIF18A-IN-10 (Compound 24) is a potent KIF18A inhibitor, with an IC50 value of 23.8 nM. KIF18A-IN-10 has anticancer activity, with IC50 values of less than 100 nM in OVCAR3 and MDA-MB-157 cells .
Cat. No.: HY-162995
CAS No.: 2991087-74-0
Target:
Research Areas:
KAT6A-IN-2 (compund 7) is a KAT6A inhibitor .
Cat. No.: HY-155755
Research Areas:
CES2A-IN-1 (compound 20w) is a potent CES2A inhibitor with an IC50 value of 1.6 nM for human CES2A. CES2A-IN-1, a bysspectin A derivative, shows an approximately 1000-fold improvement over the lead compound bysspectin A .
Cat. No.: HY-162597
Target:
Research Areas:
Dyrk1A-IN-9 (Compound L9) is a moderately active DYRK1A inhibitor (IC50: 1.67 μM). L9 shows neuroprotective activity by regulating the expression of Aβ and phosphorylation of Tau protein. Dyrk1A-IN-9 can be used for research of Alzheimer's disease .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
